A workshop focused on deep learning and machine learning will be held at the Downtown Library Complex, Room 104, on April 8 and 9, 2026. This event aims to equip participants with essential skills in the rapidly evolving field of artificial intelligence (AI) and its applications in clinical settings.
Recent data highlights significant challenges within the pharmaceutical sector regarding the deployment of AI models. The global average cost of Phase 3 development programs has now exceeded $1.2 billion, raising concerns about the efficiency of current practices. Furthermore, fewer than 12% of surveyed pharmaceutical organizations have implemented formal drift detection mechanisms for their production clinical AI models, which is critical for maintaining model accuracy over time.
The average period between deployment and database lock for these Phase 3 programs is approximately 28 months. This lengthy timeline underscores the need for improved operational practices in the integration of AI technologies.
Organizations that have adopted feature stores report a median 43% reduction in duplicated feature engineering efforts across model teams, indicating that better infrastructure can lead to more efficient workflows. The FDA’s proposed Predetermined Change Control Plan framework suggests a move towards pre-approved protocols for updating AI models in production, which could further streamline processes.
MLOps, which applies DevOps principles to AI, emphasizes the necessity for robust infrastructure to deploy, update, and monitor AI models effectively. The productive deployment of AI in clinical data operations is contingent on the maturation of MLOps infrastructure, which remains a work in progress.
The pharmaceutical industry has invested substantially in machine learning applications, including query prediction, anomaly detection, risk signal generation, and protocol digitization. However, experts warn that without continuous monitoring and drift detection, models may degrade invisibly.
One expert noted, “The result is a widening gap between the potential value of clinical AI and its realized operational contribution.” Another emphasized, “The question is whether the AI your organization deploys will still be working accurately, reliably, and defensibly two years after deployment.” These statements reflect the urgent need for advancements in AI monitoring and management.
As the workshop approaches, participants are expected to engage in discussions about these pressing issues and explore solutions that could enhance the effectiveness of AI in clinical applications.
